Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharina Hansel

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Clinical Drug Investigation|July 1, 2010
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuationAnnalisa Arcese, Nicola Aste, Alberta Bettacchi, et al.
Clinical, Cosmetic and Investigational Dermatology|April 10, 2023
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME StudyMarina Talamonti, Filomena Russo, Giovanna Malara, et al.
Dermatology and Therapy|January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian StudyFederico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Italian Journal of Dermatology and Venereology|April 23, 2024
The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergensLuca Stingeni, Leonardo Bianchi, Elena S Caroppo, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
American Journal of Clinical Dermatology|September 19, 2023
AtopyReg<sup>®</sup>, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment HistoryLuca Stingeni, Andrea Chiricozzi, Piergiacomo Calzavara-Pinton, et al.
Archives of Dermatological Research|May 23, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology|February 3, 2025
Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter ExperienceFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Journal of Clinical Medicine|March 27, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis PhenotypesFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Dermatology and Therapy|July 1, 2022
Update on the Management of Pediatric Psoriasis: An Italian ConsensusKetty Peris, Anna Belloni Fortina, Luca Bianchi, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Clinical Drug Investigation|July 1, 2010
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuationAnnalisa Arcese, Nicola Aste, Alberta Bettacchi, et al.
Clinical, Cosmetic and Investigational Dermatology|April 10, 2023
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME StudyMarina Talamonti, Filomena Russo, Giovanna Malara, et al.
Dermatology and Therapy|January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian StudyFederico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Italian Journal of Dermatology and Venereology|April 23, 2024
The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergensLuca Stingeni, Leonardo Bianchi, Elena S Caroppo, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
American Journal of Clinical Dermatology|September 19, 2023
AtopyReg<sup>®</sup>, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment HistoryLuca Stingeni, Andrea Chiricozzi, Piergiacomo Calzavara-Pinton, et al.
Archives of Dermatological Research|May 23, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology|February 3, 2025
Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter ExperienceFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Journal of Clinical Medicine|March 27, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis PhenotypesFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Dermatology and Therapy|July 1, 2022
Update on the Management of Pediatric Psoriasis: An Italian ConsensusKetty Peris, Anna Belloni Fortina, Luca Bianchi, et al.
Pageof 7